Tecan Collaborates with Arizona State University to Rapidly Assess Radiation Exposure
News May 04, 2010
Tecan is collaborating with Arizona State University (ASU) to develop the Integrated Biodosimetry System, a prototype robotic system for high throughput screening to measure an individual’s level of exposure to radiation in the event of a radiological or nuclear incident.
The project, involving several prestigious organizations, is supported by the US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA), and focuses on development of a system to enable triage of patients than is currently possible. Tecan, the ASU Biodesign Institute and its partners hope to demonstrate proof-of-concept of the platform technology by the end of the current contract period.
Dr Carl Yamashiro, principal investigator at ASU’s Biodesign Institute, explained: “The research team will work with Tecan on building a comprehensive high throughput system, allowing scientists to analyze blood samples from up to 2,000 people per day, per instrument. The beauty of our system is its versatility. Not only will we be developing a system for the effective response to a nuclear or radiological event that could affect a large population, but the high throughout platform can also be used to advance genomics testing and other routine laboratory procedures that measure gene expression levels.”
Peter Siesel, Vice President of Sales and Marketing at Tecan, said: “We are pleased and excited to be part of this impressive collaboration. Tecan has a long history of providing world-class automation solutions for our partners and customers. This project is especially important because of its significance to the defense and protection of the US population.”
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Big-Data Analysis Points Toward New Drug Discovery MethodNews
A research team has developed a computational method to systematically probe massive amounts of open-access data to discover new ways to use drugs, including some that have already been approved for other uses.
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018